{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:50:00Z","timestamp":1765954200562,"version":"3.48.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Visceral crisis in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer poses a therapeutic challenge, traditionally managed with chemotherapy due to the urgency of organ dysfunction. However, recent evidence suggests that cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i), in combination with endocrine therapy (ET), may offer rapid and effective disease control even in aggressive presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report the case of a 52-year-old premenopausal woman diagnosed with\n                      <jats:italic>de novo<\/jats:italic>\n                      HR+, HER2-negative metastatic lobular breast cancer presenting with severe anemia and thrombocytopenia secondary to diffuse bone marrow infiltration. The patient was initially managed with letrozole and goserelin, followed by the addition of ribociclib. Clinical and hematologic parameters improved rapidly, and the patient achieved a complete metabolic response after nine treatment cycles without significant toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights bone marrow infiltration as a form of visceral crisis, reinforcing the heterogeneity of visceral crisis presentations beyond solid organ involvement. The rapid response and sustained disease control observed with CDK4\/6i plus ET challenge the traditional paradigm favoring chemotherapy in such scenarios. Supporting evidence from RIGHT Choice, ABIGAIL, and recent case series further validates this therapeutic approach in carefully selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CDK4\/6 inhibitors in combination with endocrine therapy may constitute an effective and well-tolerated alternative to chemotherapy in HR+\/HER2\u2212 metastatic breast cancer presenting with visceral crisis, including hematologic compromise due to bone marrow involvement. This case underscores the need to reconsider current treatment algorithms to include targeted therapies as a viable and effective option in acute and life-threatening presentations of HR+\/HER2\u2212 metastatic breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1669057","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:45:24Z","timestamp":1765953924000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ribociclib plus endocrine therapy in bone marrow visceral crisis: challenging the chemotherapy paradigm in luminal metastatic breast cancer\u2014a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Oscar Ivan","family":"P\u00e9rez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Lendinez-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Jim\u00e9nez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Leon-Fradejas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fernandez-Garay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.01.017","article-title":"Epidemiology of de novo metastatic breast cancer","volume":"21","author":"Daily","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/J.SENOL.2024.100593","article-title":"A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain","volume":"37","author":"Vega","year":"2024","journal-title":"Rev Senol Y Patol Mamaria"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B4","unstructured":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer.\n          \n          \n          \n          2025"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14740\/WJON1043W","article-title":"Visceral crisis means short survival among patients with luminal A metastatic breast cancer: A retrospective cohort study","volume":"8","author":"Sbitti","year":"2017","journal-title":"World J Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0162","article-title":"Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: Focus on special considerations and latest advances","volume":"24","author":"Bardia","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2024.100362","article-title":"Visceral crisis in metastatic breast cancer: an old concept with new perspectives","volume":"79","author":"Andrade","year":"2024","journal-title":"Clinics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.1048781","article-title":"Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100409","article-title":"Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival","volume":"7","author":"Miglietta","year":"2022","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2261","article-title":"LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive\/HER2-negative advanced breast cancer (HR+\/HER2- ABC) with aggressive disease criteria","volume":"35","author":"de la Haba Rodriguez","year":"2024","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/S10549-023-07035-6","article-title":"CDK4\/6 inhibitors versus weekly paclitaxel for treatment of ER+\/HER2- advanced breast cancer with impending or established visceral crisis","volume":"202","author":"Behrouzi","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/S13256-024-04922-4","article-title":"First-line endocrine therapy combined with CDK 4\/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report","volume":"18","author":"Pangarsa","year":"2024","journal-title":"J Med Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/CURRONCOL29120756","article-title":"CDK4\/6 inhibitors as upfront treatment in a patient with breast cancer presenting with a clinical critic situation: A case report and review of the literature","volume":"29","author":"Targato","year":"2022","journal-title":"Curr Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.1009352","article-title":"Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive\/HER2-negative metastatic breast cancer with visceral crisis: A case report","volume":"12","author":"Schettini","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2023.2279831","article-title":"Case series of metastatic breast cancer patients with visceral crisis treated with CDK4\/6 inhibitors","volume":"36","author":"Meegdes","year":"2024","journal-title":"J Chemother"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-LB1-03","article-title":"LB1-03: Primary results of the randomised phase III trial comparing first line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-\/HR+ metastatic breast cancer and indication for chemotherapy\u2014PADMA study","volume-title":"Clin Cancer Res","author":"Loibl","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00006-3","article-title":"Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study","volume":"26","author":"Ahn","year":"2025","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad337","article-title":"CDK4\/6-inhibitors versus chemotherapy in advanced HR+\/HER2-negative breast cancer: results and correlative biomarker analyses of the KENDO randomized phase II trial","volume":"29","author":"Schettini","year":"2024","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:45:36Z","timestamp":1765953936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1669057"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1669057","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1669057"}}